Enagas SA (ENGGF) reports robust earnings with significant debt reduction and strategic growth through key acquisitions, despite regulatory and geopolitical challenges.

Enagás is acquiring a 31.5% stake in France’s Teréga while divesting part of its renewable arm to sharpen its focus on regulated infrastructure and hydrogen development.

With no single headline event on the calendar, Enagás (BME:ENG) is drawing attention after a recent share move. This is encouraging investors to reconsider how its current valuation lines up with its fundamentals. See our latest analysis for Enagás. The recent 1.30% 1 day share price return, with the stock now at €14.81, sits within a steady trend that includes a 10.03% 90 day share price return and a 21.44% 1 year total shareholder return. This hints that sentiment has been gradually...

Enagás is utilising Emerson's AspenTech digital grid management solutions to operate and improve Spain's national gas transmission network.

Enagas SA (ENGGF) surpasses 2025 targets with robust financial results and strategic progress in green hydrogen, despite regulatory uncertainties.

Enagás (BME:ENG) Catches the Eye: Is It Time to Reconsider? Enagás (BME:ENG) has recently made headlines as investors sift through its performance numbers and reassess their stance on Spain’s natural gas giant. With its market price seeing only moderate shifts in the past month and no single event shaking things up, the attention on Enagás may seem puzzling at first. Still, sometimes it is the absence of major headlines that leaves investors questioning whether a quiet period is a sign to act...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.